Johnson & Johnson (JNJ) 2024 Earnings Analysis
Johnson & Johnson2024 Earnings Analysis
74/100
Johnson & Johnson's FY2024 10-K reflects the first full year after the Kenvue consumer-health spin-off — a leaner company focused on Innovative Medicine and MedTech. Revenue of $88.8B and net income of $14.1B translate to 19.7% ROE and $19.9B FCF. The dominant strategic event is pending: STELARA, JNJ's $10B+ immunology blockbuster, entered biosimilar competition in 2025, and the 10-K's Risk Factors open by acknowledging that 'for the Company's Innovative Medicine businesses, loss of patent exclusivity for a product often is followed by a substantial reduction in sales.'
Core Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Gross margin of 69.1% — pharma-like despite the MedTech drag (which runs lower margins). The 10-K highlights the Innovative Medicine segment's key products: STELARA, REMICADE, DARZALEX, TREMFYA, ERLEADA, CARVYKTI — all high-margin patent-protected specialty therapeutics.
Operating cash flow of $24.3B on $14.1B net income yields 1.72x — elevated by non-cash charges (patent amortization, restructuring) that depress reported NI without affecting cash. Cash-based earnings are stronger than GAAP suggests.
Revenue of $88.8B grew modestly as the post-Kenvue baseline solidifies. Innovative Medicine and MedTech each contributed, but the growth is muted ahead of STELARA biosimilar erosion. The 10-K explicitly flags patent-cliff dynamics.
J&J spends approximately 19% of revenue on R&D — high even by pharma standards, reflecting the intensive reinvestment required to replace STELARA and build the next immunology/oncology franchise. The 10-K documents an extensive pipeline across immunology, oncology (CARVYKTI, DARZALEX, TECVAYLI), and pulmonary hypertension (OPSUMIT, UPTRAVI).
Earnings quality scores 79/100. The 69.1% gross margin and 1.72x cash conversion signal high-quality underlying economics, but the top-line deceleration to +4.7% previews the STELARA patent-cliff headwind. The 10-K is explicit about this: 'loss of patent exclusivity for a product often is followed by a substantial reduction in sales as competitors gain regulatory approval for generic, biosimilar and other competing products.' FY2024 shows J&J earning at near-peak on STELARA before the biosimilar rebalance; the quality metrics will look different in FY2025-26 as biosimilar competitors ramp.
Moat Strength
The 10-K lists 15+ key products protected by patents, each backed by 'a significant number of patents in the U.S. and other countries relating to their products, product uses, formulations and manufacturing processes.' But the filing also acknowledges 'patent challenges from third parties, including challenges seeking to manufacture and market generic and biosimilar' — the moat is strong per molecule but expires on fixed timelines.
Therapeutic franchises across Immunology (STELARA, TREMFYA, REMICADE), Oncology (DARZALEX, CARVYKTI, ERLEADA), and Cardiovascular (XARELTO, OPSUMIT) generate recurring prescription-driven revenue from installed physician/patient relationships. Multi-year specialty therapy lock-in is real — oncologists don't casually switch CAR-T protocols.
J&J's MedTech portfolio (cardiovascular, orthopaedics, surgery, vision — including ACUVUE contact lenses and TECNIS intraocular lenses) embeds surgeons into procedure-specific technology. The 10-K highlights orthopaedic implants, electrophysiology (Abiomed), and Shockwave — hardware + training creates multi-year switching costs.
The 10-K discloses J&J operates '64 manufacturing facilities' and sources from 'thousands of suppliers around the world.' This manufacturing footprint supports both Innovative Medicine and MedTech. The scale-based reliability (essential for FDA-regulated products) is itself a moat.
Moat strength scores 78/100 — strong but facing the largest patent cliff in J&J's modern history. The Innovative Medicine franchise is formidable on FY2024 numbers, but the 10-K's explicit Risk Factor about 'loss of patent exclusivity' applies directly to STELARA, which is already under biosimilar pressure. MedTech provides diversification — surgeon training and procedure-specific workflows create real switching costs. The 64-facility manufacturing footprint adds scale reliability that smaller competitors can't match. The moat's width depends on whether the post-Kenvue pipeline (CARVYKTI, TREMFYA expansion, next-gen oncology) fills the STELARA void by FY2027.
Capital Allocation
FCF of $19.9B on $88.8B revenue = 22.4% FCF margin. OCF-to-FCF gap is just $4.4B (CapEx), reflecting the pharma/medtech capital profile — most spending is R&D-expensed, not capitalized.
ROE of 19.7% (NI $14.1B / Equity $71.5B) — solid quality return, not engineered with excessive leverage. Debt ratio of 60.3% is moderate given the steady cash flows and predictable pharma/medtech economics.
Goodwill of $44.2B = 24.5% of $180.1B assets — elevated, reflecting J&J's acquisition-heavy pipeline building (Abiomed, Shockwave, various specialty pharma). Not alarming for a pharma, but worth monitoring as the STELARA cliff tests the earning power of acquired franchises.
J&J is a dividend aristocrat with 62+ consecutive years of raises — a commitment that signals management's capital-allocation discipline. The dividend is covered multiple times by FCF of $19.9B, leaving room for buybacks and strategic tuck-in M&A.
Capital allocation scores 76/100. The post-Kenvue J&J is structured for capital return: 19.7% ROE without Apple-style leverage, $19.9B FCF funding a multi-decade dividend-growth record, and moderate 60.3% debt ratio. The 24.5% goodwill ratio is elevated — typical of a pharma that grows via tuck-in M&A — but creates impairment exposure if acquired franchises underdeliver against STELARA's patent cliff. The test over FY2025-27 is whether R&D (~19% of revenue) converts into Carvykti/Tremfya growth that offsets the STELARA decline, or whether management needs larger M&A to fill the gap.
Key Risks
STELARA generated $10B+ in FY2023 sales; biosimilar competition began entering in 2025. The 10-K states: 'loss of patent exclusivity for a product often is followed by a substantial reduction in sales as competitors gain regulatory approval for generic, biosimilar and other competing products.' STELARA is the single most important revenue event shaping FY2025-27 earnings.
Post-reorganization, J&J continues to manage talc-related claims through various legal vehicles. Accrued legal liabilities appear on the balance sheet and remain a tail risk, though materially reduced from peak exposure. The 10-K's legal proceedings disclosure remains extensive.
The 10-K documents ambitious pipeline assets — CARVYKTI (CAR-T multiple myeloma), TECVAYLI (bispecific antibody), expanded TREMFYA indications — but clinical trial and regulatory timelines create binary risk. Whether the pipeline fills the STELARA void by FY2027 determines the growth trajectory.
The 10-K warns: 'Manufacturing disruptions can occur for many reasons including regulatory action, production quality deviations or safety issues, labor disputes, labor shortages, site-specific incidents (such as fires), natural disasters, raw material shortages, lack of available inspectors.' With 64 facilities and thousands of suppliers, correlated disruption risk (e.g., a raw material shortage affecting multiple products) exists.
Risk profile scores 64/100 (higher = safer). The STELARA patent cliff is the dominant near-term risk — the 10-K's own Risk Factors put this front and center. Biosimilar competition in 2025 will materially dent FY2025-26 revenue, and J&J's pipeline response (CARVYKTI ramp, TREMFYA expansion) is the critical offset. The residual talc litigation exposure is smaller than peak but not extinguished. The 24.5% goodwill ratio adds impairment risk if the M&A-built portfolio underperforms. Talent-, manufacturing-, and regulatory-related risks are the steady-state headwinds the 10-K catalogs carefully.
Management
Ask about this section
This analysis is for educational purposes only and does not constitute investment advice.